Introduction
============

Alzheimer\'s disease (AD) is the most common of all dementias, reaching approximately 70% of the total number of dementia cases ([@b1-etm-0-0-7071]). Dementia is characterized by impaired memory, abnormal behavior and slow thinking, due to the death of nerve cells in the brain or their inability to function normally ([@b2-etm-0-0-7071]). With the development of the disease, memory, self-care and motor ability decline, and emotionally continue to increase until death ([@b3-etm-0-0-7071]). According to statistics, there were approximately 35 million AD patients in the world in 2010, and the number of it was expected to double in 20 years ([@b4-etm-0-0-7071]). The disease characteristic of AD is sporadic, and only 5% of patients is caused by genetic mutations; it has the characteristic of early onset, patients usually fall ill before the age of 65, and individual cases even fall ill at the age of 30 ([@b5-etm-0-0-7071]). It is very urgent for drugs, that are able to effectively treat AD, to come onto the market, because of its high incidence, poor quality of life of patients, high cost of nursing treatment and long nursing cycle ([@b6-etm-0-0-7071]).

It has been reported that high homocysteine (Hcy) is involved in the occurrence and development of AD and correlated with mental diseases worldwide. The high Hcy level can cause damage to vascular endothelial cells and vascular wall structure and cause blood clotting or form thrombosis, thus leading to cardiovascular and cerebrovascular disease and dementia. It is possible that the toxic effect caused by the product of blocked Hcy methylation leads to behavioral and psychological symptoms ([@b7-etm-0-0-7071]--[@b9-etm-0-0-7071]).

Donepezil hydrochloride is an acetylcholinesterase inhibitor with reversibility and relative specificity ([@b10-etm-0-0-7071]). Donepezil hydrochloride can effectively inhibit acetylcholine degradation in the central nervous system, increase acetylcholine concentration in the synaptic space of nerve cells, improve the nerve conduction function and enhance the transmission of information in the brain, thus improving the learning and memory function of the brain, having good tolerance and clinical safety ([@b11-etm-0-0-7071]). Numerous studies have shown that folic acid and vitamin B12, which can effectively reduce the Hcy level, and are important measures to prevent and treat high Hcy ([@b12-etm-0-0-7071]).

The purpose of this study was to analyze the effect of donepezil on the Hcy level in serum of AD patients and the correlation between Hcy and dyssomnia, which has important significance in clinical treatment and provides clues for the prognosis of AD patients.

Patients and methods
====================

### General information

A retrospective analysis was performed and 124 AD patients in Zhengzhou University People\'s Hospital (Zhengzhou, China) between January 2015 and October 2017 were selected as study subjects, including 64 cases in the observation group and 60 cases in the control group, and there was no significant difference in basic indexes between the two groups (P\>0.05) ([Table I](#tI-etm-0-0-7071){ref-type="table"}). The control group was treated with folic acid, vitamin B12 and memantine hydrochloride tablet, and the observation group combined with donepezil on this basis, and both groups were treated for 4 months. The mean age of all patients was 65.04±10.81 years, including 74 males and 50 females. All study subjects were diagnosed by imaging and biochemical indexes and in accordance with AD-related diagnostic criteria ([@b13-etm-0-0-7071]). Mental diseases were excluded such as brain dysfunction and depression and diseases combined with coronary heart disease, cerebral thrombosis and liver and kidney insufficiency were also excluded. The clinical information of all the candidates was complete, and patients or their family members signed the informed consent. General information is provided in [Table I](#tI-etm-0-0-7071){ref-type="table"}.

The study was approved by the Ethics Committee of Zhengzhou University People\'s Hospital (Zhengzhou, China).

### Reagents and instruments

ELISA kit (cat. no. ml024045) was purchased from Shanghai Enzyme-linked Biotechnology Co., Ltd. (Shanghai, China); Antus PHOMO automatic enzymatic marker from Shanghai Sentient Life Science Development Co., Ltd. (Shanghai, China); donepezil hydrochloride tablet from Wei Wood Pharmaceutical Co., Ltd., guo yao zhun zi H20070181; folic acid from Tianjin Lisheng Pharmaceutical Co., Ltd. (Tianjin, China), guo yao zhun zi H12020215; vitamin B12 from Shanxi Yunpeng Pharmaceutical Co., Ltd. (Linfen, China), guo yao zhun zi H31023025; memantine hydrochloride tablet from Zhuhai Federal Pharmaceutical Co., Ltd. (Hong Kong, China) guo yao zhun zi H20130086.

### Treatment methods

All study subjects had a light diet such as low-sugar, low-fat, and high-fiber, and maintained proper exercise and ensured adequate sleep. The observation group was treated with donepezil hydrochloride tablet combined with folic acid, vitamin B12 and memantine hydrochloride tablet. Donepezil hydrochloride tablet was used 1 time/day and 5 mg/time; folic acid 1 time/day and 10 mg/time; vitamin B12 1 time/day and 500 µg/time; memantine hydrochloride tablet was used 1 time/day and 5 mg/time in the first 3 week, and increased by 5 mg each time from the 4th week to 20 mg/time and 1 time/day. The control group was treated with folic acid, vitamin B12 and memantine hydrochloride tablet, and the method was the same as that of the observation group. Both groups were treated for 4 months.

### Detection of Hcy

A total of 3 ml fasting peripheral venous blood were taken from the patients in the observation and control groups in the morning before and after 4 months of treatment, and were centrifuged at 2,600 × g for 8 min at 4°C. The serum was used for the detection of the Hcy level using ELISA method. The specific method of operation was strictly in accordance with the protocol.

### Dyssomnia score

The Pittsburgh Sleep Quality Index (PSQI) was used for the diagnosis of dyssomnia. The PSQI score criteria were 0--6 points for no dyssomnia, 7--11 points for mild dyssomnia, 12--16 points for moderate dyssomnia and 17--21 points for severe dyssomnia ([@b14-etm-0-0-7071]).

### Statistical analysis

SPSS 17.0 statistical software was used for analysis (SPSS Inc., Chicago, IL, USA). ANOVA and Dunnetts test were used for comparison between multiple groups. Chi-square test was used for enumeration data. The correlation analysis between the Hcy level in serum and dyssomnia was performed using Pearson\'s correlation analysis. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Changes in the Hcy level before and after treatment

The differences were statistically significant in the Hcy level before and after treatment between the observation and control groups (P\<0.001). The difference was not statistically significant in the Hcy level before treatment between the observation and control groups (P\>0.05). The difference was statistically significant in the Hcy level after treatment between the observation and control groups (P\<0.001) ([Fig. 1](#f1-etm-0-0-7071){ref-type="fig"}; [Table II](#tII-etm-0-0-7071){ref-type="table"}).

### Comparison of dyssomnia score before and after treatment in AD patients in the observation group

The dyssomnia score before treatment was 8.99±1.43 points, and that after treatment was 4.83±1.27 points in the observation group. The difference was statistically significant between before and after treatment in the observation group (P\<0.001) ([Fig. 2](#f2-etm-0-0-7071){ref-type="fig"}; [Table III](#tIII-etm-0-0-7071){ref-type="table"}).

### Correlation analysis between the Hcy level before and after treatment and dyssomnia in the observation group

There was a positive correlation between the Hcy level before treatment and dyssomnia score (r=0.658, P\<0.001). There was a positive correlation between the Hcy level after treatment and dyssomnia score (r=0.670, P\<0.001) ([Fig. 3](#f3-etm-0-0-7071){ref-type="fig"}; [Table IV](#tIV-etm-0-0-7071){ref-type="table"}).

Discussion
==========

According to epidemiological statistics, AD ranks fourth in fatal diseases at present, second only to heart disease. Moreover, AD-related mortality has increased to 68% ([@b15-etm-0-0-7071]). AD is the main cause of disability for the middle-aged and the elderly and their complete dependence on others ([@b16-etm-0-0-7071]). Reports worldwide have shown that high Hcy level is an independent risk factor for AD and cognitive impairment in patients, and that the AD risk is positively correlated with the Hcy level ([@b17-etm-0-0-7071],[@b18-etm-0-0-7071]). This study analyzed the effect of donepezil on the Hcy level in serum of AD patients and the correlation between Hcy and dyssomnia.

Results of this study showed that the differences were statistically significant in the Hcy level before and after treatment between the observation and control groups (P\<0.001). The difference was not statistically significant in the Hcy level before treatment between the observation and control groups (P\>0.05). The difference was statistically significant in the Hcy level after treatment between the observation and control groups (P\<0.001). It suggested that the clinical symptoms improved slowly and the effect was not particularly satisfactory in the treatment of AD patients using folic acid, vitamin B12 and memantine hydrochloride tablet, while the combined use of donepezil hydrochloride can significantly reduce the Hcy level in AD patients, indicating the effectiveness of donepezil in the treatment of AD patients. The results of Feldman ([@b19-etm-0-0-7071]) agree with us. The reason for this phenomenon is the pathogenesis of AD is that the acetylcholine in the central nervous system that promotes the decrease of the neurotransmitter level and causes dementia symptoms. Donepezil is a cholinesterase inhibitor, and *in vitro* studies have shown that donepezil has a cholinesterase inhibitory effect that is several times higher than that of butyrylcholinesterase ([@b20-etm-0-0-7071]). Therefore, the combined use of donepezil is helpful for improvement of the sensitivity of AD treatment. In this study, the dyssomnia score before treatment was 8.99±1.43 points and that after treatment was 4.83±1.27 points in the observation group. The difference was statistically significant between before and after treatment (P\<0.001). There was a positive correlation between the Hcy level before treatment and dyssomnia score (r=0.658, P\<0.001); and there was also a positive correlation between the Hcy level after treatment and dyssomnia score (r=0.670, P\<0.001). The results of Werder ([@b21-etm-0-0-7071]) are similar to ours. He believes that the high Hcy level is correlated with low levels of folic acid, vitamin B12 and behavioral and psychological symptoms of AD. The reason for this phenomenon may be: on the one hand, Hcy is transformed into homocystine in the body, which is a substance that has an excitotoxic effect on neurons; on the other hand, since the increase of the content of its own oxygen radicals promotes the formation of nitric oxide, the high concentration of Hcy is converted into neurotoxic substances and even lead to the death of neurons ([@b22-etm-0-0-7071],[@b23-etm-0-0-7071]). In addition, Hcy can significantly reduce the repair function of hippocampal neurons DNA and increase the AD risk, contributing to emotional abnormalities in patients, including dyssomnia and emotional instability ([@b24-etm-0-0-7071]).

However, there are some problems in this study. Because of the small sample size, the study was limited. Correlation analysis between the Hcy level before and after treatment in AD patients and other behavioral and psychological symptoms was not performed. Statistical analysis of the levels of folic acid, vitamin B12 and memantine hydrochloride tablet was not performed. There may be other influencing factors that still need further study.

In conclusion, donepezil can effectively improve the sleep function of patients and reduce the Hcy level in serum in the treatment of AD patients. The application of donepezil was of great significance in the clinical treatment of AD patients.
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###### 

General information (n, %).

  Factors                                Observation group (n=64)   Control group (n=60)   χ^2^    P-value
  -------------------------------------- -------------------------- ---------------------- ------- ---------
  Age (years)                                                                                      
    ≥65                                  52 (81.25)                 50 (83.33)             0.817   0.092
    \<65                                 12 (18.75)                 10 (16.67)                     
  Sex                                                                                              
    Male                                 35 (54.69)                 39 (65.00)             0.275   1.369
    Female                               29 (45.31)                 21 (35.00)                     
  Course of disease (years)                                                                        
    ≥2                                   48 (75.00)                 43 (71.67)             0.690   0.176
    \<2                                  16 (25.00)                 17 (28.33)                     
  Mean Hamilton depression scale score                                                             
    ≥12                                  38 (59.38)                 40 (66.67)             0.459   0.706
    \<12                                 26 (40.62)                 20 (33.33)                     
  Mean simple mental examination score                                                             
    ≥13                                  33 (51.56)                 29 (48.33)             0.857   0.129
    \<13                                 31 (48.44)                 31 (51.67)                     
  Bereft                                                                                           
    Yes                                  50 (78.13)                 53 (88.33)             0.155   2.294
    No                                   14 (21.87)                 7 (11.67)                      
  Live alone                                                                                       
    Yes                                  43 (67.19)                 39 (65.00)             0.851   0.066
    No                                   21 (32.81)                 21 (35.00)                     
  Blood pressure (mmHg)                                                                            
    Systolic pressure                    130.24±8.24                132.58±9.15            1.498   0.137
    Diastolic pressure                   84.35±6.25                 82.07±6.81             1.944   0.054
  β-amyloid (ng/ml)                      2.17±1.61                  2.26±1.04              0.367   0.714
  Cystine protease inhibitor C (mg/l)    1.06±0.08                  1.07±0.06              0.783   0.435
  Blood sugar (mmol/l)                   5.73±0.94                  5.64±1.08              0.496   0.621

###### 

Changes in the Hcy level before and after treatment.

  Groups        No. of cases   Treatment time   Hcy (µmol/l)                                              t value   P-value
  ------------- -------------- ---------------- --------------------------------------------------------- --------- ---------
  Observation   64             Before           26.02±3.05                                                40.70     \<0.001
                               After            6.86±2.21^[a](#tfn1-etm-0-0-7071){ref-type="table-fn"}^             
  Control       60             Before           26.12±3.11                                                25.54     \<0.001
                               After            15.65±0.64                                                          

P\<0.001, compared to the Hcy level after treatment in the control group. Hcy, homocysteine.

###### 

Comparison of dyssomnia score before and after treatment in AD patients in the observation group.

  Groups             No. of cases   Dyssomnia score   t value   P-value
  ------------------ -------------- ----------------- --------- ---------
  Before treatment   64             8.99±1.43         16.81     \<0.001
  After treatment    64             4.83±1.27                   

AD, Alzheimer\'s disease.

###### 

Correlation analysis between the Hcy level before and after treatment and dyssomnia.

  Groups               Treatment time   Hcy (µmol/l)   Dyssomnia score   r       P-value
  -------------------- ---------------- -------------- ----------------- ------- ---------
  Observation (n=64)   Before           26.02±3.05     8.99±1.43         0.658   \<0.001
                       After            6.86±2.21      4.83±1.27         0.670   \<0.001

Hcy, homocysteine.
